Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Receivables - Other (2020 - 2025)

Historic Receivables - Other for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $4.6 million.

  • Barinthus Biotherapeutics' Receivables - Other fell 6904.94% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 6904.94%. This contributed to the annual value of $7.1 million for FY2024, which is 4545.64% up from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported Receivables - Other of $4.6 million as of Q3 2025, which was down 6904.94% from $4.5 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' Receivables - Other's 5-year high stood at $17.0 million during Q2 2022, with a 5-year trough of $2.5 million in Q1 2023.
  • Moreover, its 5-year median value for Receivables - Other was $4.6 million (2025), whereas its average is $5.8 million.
  • Per our database at Business Quant, Barinthus Biotherapeutics' Receivables - Other surged by 27402.37% in 2022 and then plummeted by 8159.9% in 2023.
  • Barinthus Biotherapeutics' Receivables - Other (Quarter) stood at $6.2 million in 2021, then dropped by 27.1% to $4.5 million in 2022, then increased by 8.08% to $4.9 million in 2023, then skyrocketed by 45.46% to $7.1 million in 2024, then crashed by 35.1% to $4.6 million in 2025.
  • Its Receivables - Other was $4.6 million in Q3 2025, compared to $4.5 million in Q2 2025 and $3.0 million in Q1 2025.